EP1244707A1 - Anticorps diriges contre les proteines regulatrices de signal - Google Patents

Anticorps diriges contre les proteines regulatrices de signal

Info

Publication number
EP1244707A1
EP1244707A1 EP00979567A EP00979567A EP1244707A1 EP 1244707 A1 EP1244707 A1 EP 1244707A1 EP 00979567 A EP00979567 A EP 00979567A EP 00979567 A EP00979567 A EP 00979567A EP 1244707 A1 EP1244707 A1 EP 1244707A1
Authority
EP
European Patent Office
Prior art keywords
deposit
sirp
international
cells
date
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00979567A
Other languages
German (de)
English (en)
Inventor
Hans-Jörg BÜHRING
Axel Ullrich
Zhengjun Chen
Charles Cant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eberhard Karls Universität Tübingen
Max-Planck-Gesellschaft zur Förderung der Wissenschaften eV
Universitätsklinikum Tübingen
Original Assignee
Eberhard Karls Universität Tübingen
Max-Planck-Gesellschaft zur Förderung der Wissenschaften eV
Universitätsklinikum Tübingen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10010616A external-priority patent/DE10010616A1/de
Application filed by Eberhard Karls Universität Tübingen, Max-Planck-Gesellschaft zur Förderung der Wissenschaften eV, Universitätsklinikum Tübingen filed Critical Eberhard Karls Universität Tübingen
Publication of EP1244707A1 publication Critical patent/EP1244707A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Definitions

  • the present invention relates to monoclonal antibodies which bind specifically to the extracellular domain of the cell surface glycoproteins SIRP.
  • SIRP Signal regulator proteins
  • the two subfamilies differ in the presence or absence of a cytoplasmic domain that is capable of binding SH-2 domains.
  • the in WO 97/48723 SIRP4 and in the publication by Kharitonenkov et al. SIRP ⁇ called subfamily has such a cytoplasmic domain, while those in WO 97/48723 SIRPl and in the article by Kharitonenkov et al. SIRPß called subfamily does not have this domain.
  • Cellular signaling is a fundamental mechanism by which external stimulations that regulate various cellular processes are transmitted into the interior of cells.
  • a central biochemical mechanism of signal transmission involves the reversible phosphorylation of proteins, which regulates the activity of mature proteins by changing their structure and function.
  • protein phosphatases are involved in this process, which cleave phosphoryl groups from substrate proteins by hydrolysis, which on the other hand are transferred to the substrate proteins by protein kinases.
  • the opposite functions of protein kinases and protein phosphases regulate the signal flow in the signal transmission processes.
  • a group of the kinases involved in reversible phosphorylation are the protein tyrosine kinases of the receptor type. Tyrosine phosphatases can reduce the catalytic activity of protein kinases that are involved in cell proliferation and are therefore thought to be possible antitumor proteins. In addition, it is assumed that protein phosphatases are also involved in cellular differentiation processes.
  • SIRP ⁇ The best characterized member of the human SIRP family, SIRP ⁇ (or SIRP4) is a substrate of activated receptor tyrosine kinases. Overexpression of SIRP ⁇ leads to a reduced response to the receptor tyrosine kinase ligands EGF (epidermal growth factor), insulin and PDGF (platelet-derived growth factor).
  • SIRP acts as a negative regulator in the proliferation and differentiation of cells, so that antibodies against SIRP not only for studying the expression and function of SIRP but also in therapeutic and diagnostic applications in connection with diseases or impairments that have an irregularity in a signal transmission path can play a role.
  • WO 97/48723 generally describes a method for producing monoclonal antibodies against SIRP polypeptides, the therapeutic / diagnostic use of such antibodies also being mentioned, in particular in connection with immunological test methods.
  • monoclonal antibodies themselves are not presented in this document, in particular, no reference is made to a deposit under the Budapest Treaty. Against this background, the object of the present application is to create monoclonal antibodies of the type mentioned at the outset which bind specifically to the extracellular domain of the cell surface glycoproteins SIRP.
  • Such monoclonal antibodies are preferably produced by hybridoma cells which are selected from the group of the following hybridoma cells SE5A5 deposited on November 30, 1999, November 25, 1999 and January 13, 2000 with the German Collection of Microorganisms and Cell Cultures GmbH, DSMZ, according to the Budapest Treaty , SE7C2, SE12B6, P3C4 (all 30.11.1999), B1D5 (25.11.1999) and B4B6 (13.01.2000).
  • the invention further relates to hybridoma cells which have the ability to produce and release such an antibody.
  • the inventors of the present application have for the first time provided monoclonal antibodies and hybridoma cells which produce and release them, which enable targeted recognition and influencing of cells which have the extracellular domain of SIRP.
  • the antibodies thus provide a hitherto unique and versatile means for the doctor and researcher to detect such cells on the one hand, both in cell culture and in the patient's organism, and on the other hand to manipulate these cells if necessary, either by the antibody itself or through specific reagents coupled to it.
  • the inventors of the present application found that the antibodies SE5A5, SE7C2, SE12B6 and P3C4 bind both to polypeptides of the subfamily SIRP ⁇ and SIRPß, while the antibodies B1D5 and B4B6 only bind specifically to SIRPß.
  • the invention also relates to a monoclonal antibody which specifically binds only to the extracellular domain of SIRPß.
  • the inventors have also found that the antibodies SE5A5, SE7C2 and SE12B6 block the interaction of SIRP ⁇ with the surface marker CD47.
  • the invention further relates to a monoclonal antibody which binds specifically to the extracellular domain of SIRP ⁇ and blocks the interaction of SIRP ⁇ with the surface marker CD47.
  • CD47 is the extracellular ligand for human SIRP and that these two mutual receptors are involved in cellular adhesion, which can be blocked by the monoclonal antibodies SE5A5, SE7C2 and SE12B6.
  • SE5A5, SE7C2 and SE12B6 monoclonal antibodies
  • SE5A5, SE7C2 and SE12B6 monoclonal antibodies
  • the invention further relates to a pharmaceutical agent with one of the new antibodies, which is preferably coupled to a cellularly directed therapeutic or diagnostic agent.
  • An antibody according to the invention which is coupled to a detection means, for example a radioactive marker, indirectly binds this detection means to the corresponding cells and thus enables the direct detection of these cells, for example using X-ray diagnostic / scintigraphic methods.
  • the coupling with a therapeutically active agent can also enable a direct and targeted influencing of SIRP-carrying cells.
  • the present invention further relates to the use of an antibody according to the invention for the isolation of hematopoietic stem cells.
  • Example 1 Production and characterization of monoclonal antibodies against the cell surface glycoprotein SIRP
  • SIRP ⁇ lex SIRP ⁇ lex
  • SIRPßlex SIRPßlex
  • mice Four to eight week old female Balb / c mice are immunized three times at 14 day intervals with 15 ⁇ g protein diluted 1: 2 in RIBI adjuvant (PanSystems, Aidenbach, Germany). Four days after the last injection, the spleen was removed and fused with myeloma cells from the known strain SP2 / 0. The fused cells were cultured, the selection of specific antibodies were then carried out on a cell line transfected with SIRP ⁇ l or SIRPßl.
  • Herge ⁇ SIRP antibody Represented the reactivity and properties of the various, so Herge ⁇ SIRP antibody resulting from the attached table and the following examples.
  • the monoclonal antibodies B1D5 and B4B6 are specific for SIRPßl. All SIRP ⁇ l-specific monoclonal antibodies also react with SIRPßl, so that the antibodies SE5A5, SE7C2, SE12B6 and P3C4 can be regarded as specific for SIRP, since other members of the SIRP family have very similar extracellular domains.
  • Example 2 Expression of SIRP on bone marrow cells or peripheral blood cells
  • the monoclonal antibody P3C4 was used to investigate the surface expression of SIRP on mononuclear bone marrow cells and peripheral blood cells. Using immunofluorescence it was possible to demonstrate that the highest expression is present on monocytes, that there is medium expression on granulocytes and that there is almost no expression on lymphocytes. CD83 + dendritic cells were also very positive for SIRP.
  • SIRP myeloid / monocytic progenitor cells.
  • SIRP is also expressed on CD19 * B lymphoids and on immature CD117 + and AC133 * progenitor cells.
  • no SIRP expression was found on CD3 + T cells, CD56 * natural killer cells or glycophorin A * erythroid progenitor cells.
  • SIRP expression in the bone marrow is mainly found on myeloid and CD34 * stem cells and progenitor cells.
  • CD34 * bone marrow cells were purified by MACS and stained with antibodies against CD34, SIRP and selected CD markers. It was found that SIRP was on CD34 * CD90 * , CD34 * CD117 ⁇ and CD34 * CD164 expresses stem cells and myeloid subsets but does not express CD34 * CD19 * B cell subsets or CD34 * CD71 expresses erythroid progenitor cells, suggesting that SIRP plays a role in regulating stem cell growth and differentiation.
  • SIRP is not only involved in the function of myeloid cells, but also plays an important role in the regulation of stem cell differentiation.
  • the antibody P3C4 was also used to check the expression of SIRP on blasts of acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) using immunofluorescence.
  • AML acute myeloid leukemia
  • CML chronic myeloid leukemia
  • SIRP ⁇ lex In order to investigate the possible interaction of SIRP with cellular components on normal and malignant hematopoietic cells, cell binding tests were carried out with immobilized fusion proteins from SIRP ⁇ lex, SIRP ⁇ 2ex and SIRPßlex. All myeloblastic, monoblastic, erythroblastic, megakaryoblastic, B- and T-lymphoblastic cell lines tested strongly bound to SIRP ⁇ lex and SIRP ⁇ 2ex, but not to SIRPßlex, whereby series of dilutions showed that B- and T-lymphoblastic cell lines showed a larger number of binding sites for SIRP.
  • SIRP ligands showed strong binding of soluble SIRP ⁇ lex and SIRP ⁇ 2ex to lymphocytes, while the binding to monocytes and granulocytes was significantly weaker.
  • the SIRP were negative but strong ⁇ IRP ⁇ lex and SIRP ⁇ 2ex-binding cells CCRF-CEM used to generate monoclonal antibodies that inhibit the binding of SIRP ⁇ lex and SIRP ⁇ 2ex to these cells.
  • the antibody CC2C6 found completely blocked this binding.
  • CD47-specific monoclonal antibodies can completely block the interaction between CD47 and SIRP, while non-functional monoclonal antibodies have no effect on this interaction. This indicates that the binding of SIRP to CD47 is essential for many functions described for CD47.
  • both the blocking and the non-blocking antibodies according to the invention are valuable tools for examining the involvement of SIRP in various immunological processes in vitro.
  • the viability of the microorganism mentioned under II was checked on 200 0 - 0 1 - 19 : . At that time the microorganism was
  • This international depository accepts the microorganism designated under I, which it received on 2 0 0 0 - 0 1 - 13 (date of first deposit) 1 .
  • microorganism referred to under I was received by this international depository on (date of first filing) and an application for conversion of this first deposit into a deposit under the Budapest Treaty was received on (date of receipt of the request for conversion)
  • This international depository accepts the microorganism designated under I. which she received on 19 9 9 - 11 - 25 (date of first deposit) '
  • microorganism referred to in 1 has been received by this international depository on (date of first deposit) and an application for conversion of this initial deposit into a deposit under the Budapest Treaty has been received on (date of receipt of the application for conversion)
  • This international deposit part adopts the microorganism designated under I. which she received on 199 9 - 11 - 3 0 (date of first deposit) '.
  • microorganism referred to under I was received by this international depository on (date of first filing) and an application for conversion of this first deposit into a deposit under the Budapest Treaty was received on (date of receipt of the request for conversion)
  • This international depository accepts the microorganism designated under I. which it received on 1 9 9 9 9 - 11 - 3 0 (date of first filing)
  • microorganism referred to under I was received by this international depository on (date of first deposit) and an application for conversion of this first deposit into a deposit under the Budapest Treaty was received on (therefore the receipt of the application for conversion)
  • MIKROORG .NISMEN UND ZELL L LTURCN GmbH authorized persons (tn) or ⁇ .r es (der) from their authorized staff
  • This international depository accepts the microorganism designated under I. which she received on 1 9 9 9 - 1 1 - 3 0 (why the first filing).
  • microorganism referred to under I was received by this international depository on (date of first filing) and an application for conversion of this first deposit into a deposit under the Budapest Treaty was received on (date of receipt of the request for conversion)
  • MIKROORGANISMEN UND ZELLKULTUREN GmbH authorized Pcrson (s) or the employee (s) authorized by them
  • This international depository accepts the microorganism designated under I. which it received on 19 9 9 - 11 - 3 0 (date of first deposit) 1 .
  • microorganism referred to under I was received by this international depository on (date of first deposit) and an application for conversion of this first deposit into a deposit under the Budapest Treaty was received on (therefore the receipt of the request for conversion)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des anticorps monoclonaux qui se lient spécifiquement au domaine extracellulaire des glycoprotéines de surface cellulaire SIRP et qui, dans quelques cas, bloquent l'interaction des SIRP avec la molécules de surface CD47.
EP00979567A 1999-11-30 2000-11-16 Anticorps diriges contre les proteines regulatrices de signal Withdrawn EP1244707A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19957665 1999-11-30
DE19957665 1999-11-30
DE10010616 2000-03-03
DE10010616A DE10010616A1 (de) 1999-11-30 2000-03-03 Anitkörper gegen Signal-Regulator-Proteine
PCT/EP2000/011322 WO2001040307A1 (fr) 1999-11-30 2000-11-16 Anticorps diriges contre les proteines regulatrices de signal

Publications (1)

Publication Number Publication Date
EP1244707A1 true EP1244707A1 (fr) 2002-10-02

Family

ID=26004690

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00979567A Withdrawn EP1244707A1 (fr) 1999-11-30 2000-11-16 Anticorps diriges contre les proteines regulatrices de signal

Country Status (4)

Country Link
US (1) US6913894B2 (fr)
EP (1) EP1244707A1 (fr)
AU (1) AU1701001A (fr)
WO (1) WO2001040307A1 (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2428240A (en) * 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
JP2011500005A (ja) 2007-10-11 2011-01-06 ユニバーシティー ヘルス ネットワーク ヒト造血幹細胞の生着を増加させるためのＳＩＲＰα−ＣＤ４７相互作用の調節およびそのための化合物
EP2111869A1 (fr) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions et procédés pour renforcer le système immunitaire
DK2429574T3 (da) 2009-05-15 2015-06-22 Univ Health Network Sammensætninger og fremgangsmåder til behandling af hæmatologiske cancere der targeterer sirp-cd47-interaktionen
ME03550B (fr) 2012-12-17 2020-07-20 Trillium Therapeutics Inc Traitement de cellules tumorales à cd47+ avec des fusions sirp alpha/fc
PH12018550160B1 (en) 2016-04-14 2024-07-03 Ose Immunotherapeutics NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
CA3042581A1 (fr) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Amelioration de la therapie de blocage des cd47 par des inhibiteurs du proteasome
WO2018081898A1 (fr) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Améliorations de la thérapie de blocage de cd47 par des inhibiteurs de hdac
CN110325549B (zh) 2016-12-09 2024-03-08 艾利妥 抗SIRPα抗体及其使用方法
WO2018118887A1 (fr) 2016-12-22 2018-06-28 Wake Forest University Health Sciences Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer
JP7160833B2 (ja) * 2017-04-13 2022-10-25 サイロパ ビー．ブイ． 抗ｓｉｒｐアルファ抗体
PT3625259T (pt) 2017-05-16 2024-07-04 Synthon Biopharmaceuticals Bv Anticorpos anti-sirpalfa
EP3658589B1 (fr) 2017-07-26 2023-09-27 Forty Seven, Inc. Anticorps anti-sirp-alpha et méthodes associées
WO2019084692A1 (fr) 2017-11-06 2019-05-09 Trillium Therapeutics Inc. Blocage du cd47 associé à une radiothérapie
WO2019183266A1 (fr) 2018-03-21 2019-09-26 ALX Oncology Inc. Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation
CR20200566A (es) 2018-05-25 2021-02-19 Alector Llc Anticuerpos anti-sirpa y metodos de utilización de los mismos
AU2019293589A1 (en) 2018-06-29 2021-01-21 Alector Llc Anti-SIRP-beta1 antibodies and methods of use thereof
EP3846855B1 (fr) 2018-09-04 2024-12-04 Pfizer Inc. Blocage du cd47 avec inhibition de la parp pour le traitement de maladies
CN113412279B (zh) 2018-11-15 2024-09-24 拜奥迪斯私人有限公司 人源化抗SIRPα抗体
CN114245807B (zh) 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
PH12022550835A1 (en) 2019-10-18 2023-07-03 Forty Seven Inc Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
CN110734897A (zh) * 2019-10-31 2020-01-31 浙江蓝盾药业有限公司 杂交瘤细胞株12g6、抗体及其应用
NZ786589A (en) 2019-10-31 2025-03-28 Forty Seven Llc Anti-cd47 and anti-cd20 based treatment of blood cancer
CN115362003B (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
WO2022229818A1 (fr) 2021-04-27 2022-11-03 Pf Argentum Ip Holdings Llc Amélioration de la thérapie de blocage de cd47 avec des inhibiteurs de dhfr
WO2022245671A1 (fr) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Méthodes d'utilisation de protéines de fusion flt3l-fc
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
EP4359413A1 (fr) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Composés de modulation de la diacylglycérol kinase
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
US20240165229A1 (en) 2021-06-29 2024-05-23 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
EP4423078A1 (fr) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Dérivés de pyridine-3(2h)-one
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
US20250235504A1 (en) 2021-10-29 2025-07-24 Pfizer Inc. Enhancement of cd47 blockade with taxanes for cd47+ cancer therapy
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
CA3248911A1 (fr) 2022-01-28 2023-08-03 Gilead Sciences, Inc. Inhibiteurs de poly(adénosine diphosphate-ribose) polymérase 7
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
EP4511127A1 (fr) 2022-04-21 2025-02-26 Gilead Sciences, Inc. Composés modulateurs de kras g12d
WO2024006929A1 (fr) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Composés cd73
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024105180A1 (fr) 2022-11-16 2024-05-23 Boehringer Ingelheim International Gmbh Biomarqueurs d'efficacité prédictive pour anticorps anti-sirpa
EP4638436A1 (fr) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations
WO2024215754A1 (fr) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Composés modulateurs de kras
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
JP2026522894A (ja) 2023-06-30 2026-07-09 ギリアード サイエンシーズ， インコーポレイテッド Ｋｒａｓ調節化合物
CN121568935A (zh) 2023-07-26 2026-02-24 吉利德科学公司 Parp7抑制剂
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
EP4774280A1 (fr) 2023-09-08 2026-07-15 Gilead Sciences, Inc. Composés de modulation de kras g12d
WO2025096589A1 (fr) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (fr) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds
US20260130893A1 (en) 2024-10-21 2026-05-14 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026136515A1 (fr) 2024-12-19 2026-06-25 Gilead Sciences, Inc. Inhibiteurs de parp7

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0914452A2 (fr) * 1996-06-17 1999-05-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nouvelles proteines ptp20, pcp-2, bdp1, clk et sirp, produits et procedes connexes
CA2226962A1 (fr) * 1998-02-16 1999-08-16 Marie Sarfati Utilisation d'agents liants a cd47 et ces ligands pour le traitement ou prophylaxie de maladies inflammatoire, autoimmunitaire et allergique et pour le traitement de rejet de greffons
EP1048299A1 (fr) * 1999-04-28 2000-11-02 Faculteit der Geneeskunde van de Vrije Universiteit Procédé pour l'inhibition du fonctionemment cellulaire dans la therapie antiinflammatoire et anticancéreuse

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Lexikon der Biology", 2005, ELSEVIER, MUNICH, GERMANY *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 15 November 1997 (1997-11-15), BUEHRING ET AL: "The signal regulatory protein 1 alpha (SIRP-1alpha) is expressed on the most primitive human hematopoietic stem cell subsets" *
JACOBS N. ET AL: "EFFICIENT IMMUNOSELECTION OF CYTOLYTIC EFFECTORS WITH A MAGNETIC CELL SORTER", RESEARCH IN IMMUNOLOGY, vol. 144, no. 2, 1993, pages 141 - 150, XP008004703 *
KANTOR A.B. ET AL: "MAGNETIC CELL SORTING WITH COLLOIDAL SUPERPARAMAGNETIC", CELL SEPARATION METHODS AND APPLICATIONS, 1998, CELL SEPARATION METHODS AND APPLICATIONS, pages 153 - 173, XP000908702 *
KLUCHER K.M.; GERLACH M.J.; DALEY G.Q.: "A novel method to isolate cells with conditional gene expression using fluorescence activated cell sorting (FACS)", NUCLEIC ACIDS RESEARCH, vol. 25, no. 23, 1997, SURREY, GB, pages 4858 - 1048, XP002959483 *
RUFER N.; HELG C.; CHAPUIS B.; ROOSNEK E.: "Human memory T cells: lessons from stem cell transplantation", TRENDS IN IMMUNOLOGY, vol. 22, no. 3, 1 March 2001 (2001-03-01), pages 136 - 141, XP004255877 *
See also references of WO0140307A1 *

Also Published As

Publication number Publication date
WO2001040307A1 (fr) 2001-06-07
US20030054415A1 (en) 2003-03-20
US6913894B2 (en) 2005-07-05
WO2001040307A8 (fr) 2002-01-10
AU1701001A (en) 2001-06-12

Similar Documents

Publication Publication Date Title
WO2001040307A1 (fr) Anticorps diriges contre les proteines regulatrices de signal
DE69119278T2 (de) Monoklonaler Antikörper, der mit einer neuen HLA-Determinante auf MHC-Klasse-I-Moleküle reagiert, und Verfahren zur Aktivierung von Lymphozyten
DE19608769C1 (de) Antikörper BV10A4H2
DE69433168T2 (de) In vitro vermehrung von stammzellen
DE69127313T2 (de) Subklasse von menschlichen Vorläuferzellen
DE69735547T2 (de) Verfahren zur induzierung von immunsupprimierten zellen und vorrichtung zu deren kultivierung
DE69434097T2 (de) Apoptose induzierender monoklonaler antikörper
DE19725586C2 (de) Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
DE69504955T2 (de) Immunstimulierende monoklonale antikörper
EP1483293A2 (fr) Utilisation d'une substance active se liant a cd28 pour la preparation d'une composition pharmaceutique
EP1600460B1 (fr) Utilisation d'une substance active se liant à CD28 pour la préparation d'une composition pharmaceutique pour traitement de B-CLL
EP2313772A1 (fr) Isolement et/ou identification de cellules souches ayant un potentiel de différentiation adipocytaire, chondrocytaire et pancréatique
DE69126526T2 (de) Verfahren zur zellwachstumshinderung und dazu nützliche verbindungen
DE10050935A1 (de) Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
EP0787743A2 (fr) A3C6E2, un anticorps monoclonal contre le récepteur humain du facteur de stimulation des cellules souches
DE3939706C1 (fr)
DE69031914T2 (de) Rezeptor für granulozyten-macrophagen-koloniestimulierungsfaktor und seine derivate
DE19727814C1 (de) Anitkörper 4G8B4B12
DE60223556T2 (de) Medizinische verwendung von stammzellen, die vegfr-1 exprimieren
DE69906064T2 (de) Glycoproteine mit lipidmobilisierenden eigenschaften und deren therapeutische verwendungen
DE69434828T2 (de) Monoklonale Antikörper die Flk-2 Rezeptoren erkennen, und die Isolierung primitiver hämatopoietischer Stammzellpopulationen
DE4322570C1 (de) Stromale Zellinien aus menschlichem Knochenmark
DE3490527C2 (fr)
DE68928634T2 (de) Verfahren zur Herstellung von aktivierten Killer-Monozyten und Verfahren zur Überprüfung ihrer tumoriziden Aktivität
EP0607593A2 (fr) Procédé d'obtention de cultures cellulaires avec un taux amélioré de cytonines autogènes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020620

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CANT, CHARLES

Inventor name: ULLRICH, AXEL

Inventor name: CHEN, DR. ZHENGJUN

Inventor name: BUEHRING, HANS-JOERG

17Q First examination report despatched

Effective date: 20040607

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070110